reports
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Dir...
Krystal Biotech Announces Early Evidence of Monotherapy Activity in He...
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercia...
Krystal Biotech Inc: 2 directors
Two Directors at Krystal Biotech Inc sold 50,000 shares at between 164.781USD and 164.820USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory...
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date Conditional sanctioning of the KB407 Phase 1 CF Study CORAL-1 protocol by CFF TDN Investor call and webcast to b...
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of ...
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC...
Krystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech to Present at Upcoming Investor Conferences PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gables, Florida; fireside chat scheduled for 2:...
Krystal Biotech to Present at Stifel 2024 Healthcare Conference
Krystal Biotech to Present at Stifel 2024 Healthcare Conference PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on November 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:55 am ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:55 am ET on Monday, November 18, 2024 and will be post...
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovat...
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 1:30 pm ET on Tues...
Krystal Biotech Announces Third Quarter 2024 Financial Results and Pro...
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics’ KB301 to Phase 2 after positive results in Phase 1 Clinical updates on AATD and onco...
Krystal Biotech to Report Third Quarter 2024 Financial Results on Nove...
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 4, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For...
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:20 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 1:20 pm ET on Wednesday, September 18,...
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Inves...
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a company presentation at 12:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 12:30 pm ...
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficac...
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin, ann...
Krystal Biotech Announces Second Quarter 2024 Financial Results and Pr...
Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study (Cohorts 3 and 4) in 3Q 2024; KB408 Phase 1 SERPENTINE-1 study for the treatment of AATD in 4Q 2024; and KB707 Phase 1 OPAL-1 study for the treatment of injectable solid tumors in 4Q 2024 Strong balance sheet, ending the quarter with $628.9 million in cash and invest...
Krystal Biotech to Report Second Quarter 2024 Financial Results on Aug...
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024 PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 5, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
EBS EMERGENT BIOSOLUTIONS INC.
CDNA CAREDX INC
THS TREEHOUSE FOODS INC.
FONR FONAR CORP.
KIDS ORTHOPEDIATRICS CORP
AMD ADVANCED MICRO DEVICES INC.
KRYS KRYSTAL BIOTECH INC
MMMB MAMAMANCINI'S HOLDINGS INC
SITM SITIME
RNA AVIDITY BIOSCIENCES
PWP PERELLA WEINBERG PARTNERS
ASTS AST SPACEMOBILE INC
BRBR BELLRING BRANDS INC
INTR INTER & CO INC
EWTX EDGEWISE THERAPEUTICS INC
ACRV ACRIVON THERAPEUTICS INC
WGS GENEDX HOLDINGS CORP.
XPOF XPONENTIAL FITNESS INC
SOWG SOW GOOD INC
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthc...
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference PITTSBURGH, June 05, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:40 am ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:40 am ET on Tuesday...
Krystal Biotech to Present at the American Thoracic Society 2024 Inter...
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference being held from May 17-22, 2024 in San Diego, California. KB407 and KB408 are modified, replication-defective, non-integrating HSV-1 vectors formulated for inhaled delivery to the lun...
Krystal Biotech to Present at BofA Securities 2024 Health Care Confere...
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:20 pm PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 2:20 pm PT on Tuesday, May 14, 2024 and wil...
Krystal Biotech Announces First Quarter 2024 Financial Results and Pro...
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track Designations for both inhaled and intratumoral KB707Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 06, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the first qua...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.